Metamark Obtains Draft Medicare Coverage for ProMark
News May 20, 2016
Metamark Genetics, Inc. has announced that Palmetto GBA, Noridian Healthcare Solutions, LLC, and CGS Administrators, LLC, three Medicare Administrative Contractors (MACs) that assess novel molecular diagnostic technologies, have issued draft local coverage determinations (LCDs) for ProMark, the first and only proteomic prognostic test for early-stage prostate cancer.
The draft LCDs are posted to the Medicare Coverage Database on the Centers for Medicare & Medicaid Services (CMS) website, and propose to establish reimbursement coverage for eligible prostate cancer patients to help determine which patients can be conservatively managed rather than treated with definitive surgery or radiation therapy.
“These draft LCDs represent another significant milestone for ProMark, moving Metamark closer to our goal of ensuring that all prostate cancer patients have greater access to additional, critical information about their disease aggressiveness so they can make an appropriate and personalized treatment decision,” said Jerry Williamson, President and CEO.
“The draft LCDs closely follow ProMark’s inclusion in the 2016 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines1 in March, further demonstrating the growing adoption of ProMark as a meaningful prognostic tool in the care of patients with clinically localized prostate cancer.”
ProMark predicts cancer aggressiveness in patients with biopsy Gleason Scores of 3+3 and 3+4, providing a fully independent and individualized prediction that the cancer can be managed without aggressive treatment, or an indication that therapy may be appropriate.